{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:51:31Z","timestamp":1790484691941,"version":"4.1.0"},"reference-count":53,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T00:00:00Z","timestamp":1566777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["16EX1021N"],"award-info":[{"award-number":["16EX1021N"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>CD3+ and CD8+ lymphocytes are well known prognostic markers in primary ovarian cancer. In contrast, the predictive value of the immune infiltrate concerning treatment response and the involvement of immune heterogeneity between primary and metastatic lesions are poorly understood. In this study, the immune infiltrate of 49 primary tumors and 38 corresponding lesions in the omentum (n = 23) and the peritoneum (n = 15) was immunohistochemically analyzed and correlated with clinicopathological factors and platinum-sensitivity. Immune heterogeneity was observed between paired primary and metastatic lesions for all immune cell phenotypes. The stromal immune infiltrate was higher in the omental lesions than in the primary tumors, which was reflected by CD45 (p = 0.007), CD3 (p = 0.005), CD8 (p = 0.012), and PD-1 (programmed cell-death protein 1) (p = 0.013). A higher stromal infiltrate of both CD45+ and CD3+ cells in the omental lesions was associated with the detection of lymph node metastasis (CD45, p = 0.018; CD3, p = 0.037). Platinum-sensitive ovarian cancers revealed a higher intratumoral CD8+ infiltrate in the peritoneal lesions compared to the primary tumors (p = 0.045). In contrast, higher counts of stromal PD-1+ cells in the peritoneal lesions have been associated with reduced platinum-sensitivity (p = 0.045). Immune heterogeneity was associated with platinum response and might represent a selection marker for personalized therapy.<\/jats:p>","DOI":"10.3390\/cancers11091250","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T10:54:53Z","timestamp":1566816893000},"page":"1250","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer"],"prefix":"10.3390","volume":"11","author":[{"given":"Katharina","family":"D\u00f6tzer","sequence":"first","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians-University Munich, Marchioninistra\u00dfe 15, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Schl\u00fcter","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians-University Munich, Marchioninistra\u00dfe 15, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5806-8249","authenticated-orcid":false,"given":"Markus Bo","family":"Schoenberg","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians-University Munich, Marchioninistra\u00dfe 15, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandr V.","family":"Bazhin","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians-University Munich, Marchioninistra\u00dfe 15, 81377 Munich, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Munich, Pettenkoferstra\u00dfe 8a, 80336 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Edler von Koch","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Klinikum Dritter Orden, Menzinger Stra\u00dfe 44, 80638 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schnelzer","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University Munich, Ismaninger Stra\u00dfe 22, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Anthuber","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Clinic Starnberg, O\u00dfwaldstra\u00dfe 1, 82319 Starnberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Grab","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Clinic Harlaching, Sanatoriumsplatz 2, 81545 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6589-4736","authenticated-orcid":false,"given":"Bastian","family":"Czogalla","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Marchioninistra\u00dfe 15, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Burges","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Marchioninistra\u00dfe 15, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians-University Munich, Marchioninistra\u00dfe 15, 81377 Munich, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Munich, Pettenkoferstra\u00dfe 8a, 80336 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Mahner","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Marchioninistra\u00dfe 15, 81377 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians-University Munich, Marchioninistra\u00dfe 15, 81377 Munich, Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Munich, Pettenkoferstra\u00dfe 8a, 80336 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"15621","DOI":"10.18632\/oncotarget.14919","article-title":"The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_2","unstructured":"OTTA Consortium (2017). Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol., 3, e173290."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women with Advanced Epithelial Ovarian Cancer: Three-Year Results","volume":"92","author":"Piccart","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"12389","DOI":"10.18632\/oncotarget.13310","article-title":"Bevacizumab in ovarian cancer: A critical review of phase III studies","volume":"8","author":"Rossi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_7","unstructured":"National Institute for Health and Care Excellence (2019, June 03). Topotecan, Pegylated Liposomal Doxorubicin Hydrochloride, Paclitaxel, Trabectedin and Gemcitabine for Treating Recurrent Ovarian Cancer. Available online: https:\/\/www.nice.org.uk\/guidance\/ta389."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.3747\/co.24.3824","article-title":"Systemic therapy for recurrent epithelial ovarian cancer: A clinical practice guideline","volume":"24","author":"Francis","year":"2017","journal-title":"Curr. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1200\/JCO.2016.34.15_suppl.5533","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent\/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity","volume":"34","author":"Disis","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients with Platinum-Resistant Ovarian Cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1200\/jco.2015.33.15_suppl.5510","article-title":"Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study","volume":"33","author":"Varga","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40661-016-0033-6","article-title":"The role of immune checkpoint inhibition in the treatment of ovarian cancer","volume":"3","author":"Gaillard","year":"2016","journal-title":"Oncol. Res. Pract."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/path.4230","article-title":"Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling","volume":"231","author":"Bashashati","year":"2013","journal-title":"J. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/path.4819","article-title":"Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling","volume":"241","author":"Choi","year":"2017","journal-title":"J. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1101\/gr.161026.113","article-title":"Genomic and transcriptomic plasticity in treatment-naive ovarian cancer","volume":"24","author":"Hoogstraat","year":"2014","journal-title":"Genome Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/PGP.0b013e31820d20ba","article-title":"Biomarker expression in pelvic high-grade serous carcinoma: Comparison of ovarian and omental sites","volume":"30","author":"Turbin","year":"2011","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"R303","DOI":"10.1530\/ERC-17-0336","article-title":"Biomarkers of platinum resistance in ovarian cancer: What can we use to improve treatment","volume":"25","author":"Tang","year":"2018","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"22832","DOI":"10.18632\/oncotarget.25126","article-title":"Role of tumor microenvironment in ovarian cancer pathobiology","volume":"9","author":"Ghoneum","year":"2018","journal-title":"Oncotarget"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fonc.2017.00024","article-title":"The Unique Molecular and Cellular Microenvironment of Ovarian Cancer","volume":"7","author":"Worzfeld","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"17501","DOI":"10.18632\/oncotarget.24770","article-title":"BRCA1\/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer","volume":"9","author":"Wieser","year":"2018","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00428-011-1110-1","article-title":"Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy","volume":"459","author":"Bosmuller","year":"2011","journal-title":"Virchows Arch."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1158\/1078-0432.CCR-14-1298","article-title":"Cisplatin-induced antitumor immunomodulation: A review of preclinical and clinical evidence","volume":"20","author":"Adusumilli","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.31200","article-title":"Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications","volume":"143","author":"Khairallah","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/0008-5472.CAN-12-2225","article-title":"Dose-dense chemotherapy improves mechanisms of antitumor immune response","volume":"73","author":"Chang","year":"2013","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1158\/1078-0432.CCR-16-2366","article-title":"Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer","volume":"23","author":"Chatterjee","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13048-018-0414-z","article-title":"Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer","volume":"11","author":"Drakes","year":"2018","journal-title":"J. Ovarian Res."},{"key":"ref_32","first-page":"S161","article-title":"Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.it.2017.03.002","article-title":"Immunological Functions of the Omentum","volume":"38","author":"Randall","year":"2017","journal-title":"Trends Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ajpath.2013.04.023","article-title":"Milky spots promote ovarian cancer metastatic colonization of peritoneal adipose in experimental models","volume":"183","author":"Clark","year":"2013","journal-title":"Am. J. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"McCloskey, C.W., Rodriguez, G.M., Galpin, K.J.C., and Vanderhyden, B.C. (2018). Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics. Cancers, 10.","DOI":"10.3390\/cancers10080244"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1158\/2326-6066.CIR-16-0042","article-title":"Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer","volume":"4","author":"Wei","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ccell.2016.03.005","article-title":"Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients","volume":"29","author":"Halama","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41419-018-0796-2","article-title":"CCL5-deficiency enhances intratumoral infiltration of CD8(+) T cells in colorectal cancer","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"71123","DOI":"10.18632\/oncotarget.12106","article-title":"Similarity and diversity of the tumor microenvironment in multiple metastases: Critical implications for overall and progression-free survival of high-grade serous ovarian cancer","volume":"7","author":"Heindl","year":"2016","journal-title":"Oncotarget"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2017.07.025","article-title":"Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient","volume":"170","author":"Memon","year":"2017","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","article-title":"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"17","author":"Kristensen","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/IGC.0000000000001221","article-title":"Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (>\/=70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study","volume":"28","author":"Selle","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/annonc\/mdv500","article-title":"Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology\/Gynecologic Oncology Group study","volume":"27","author":"Tewari","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_45","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF) (2019, June 03). S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Langversion 3.0. Available online: https:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/ovarialkarzinom\/."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0016-5085(96)70004-5","article-title":"High expression of a Lewis(x)-related epitope in gastric carcinomas indicates metastatic potential and poor prognosis","volume":"111","author":"Mayer","year":"1996","journal-title":"Gastroenterology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"114935","DOI":"10.18632\/oncotarget.22932","article-title":"Development of a reliable and accurate algorithm to quantify the tumor immune stroma (QTiS) across tumor types","volume":"8","author":"Miksch","year":"2017","journal-title":"Oncotarget"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00428-012-1232-0","article-title":"An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancer","volume":"460","author":"Vayrynen","year":"2012","journal-title":"Virchows Arch."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Miksch, R.C., Schoenberg, M.B., Weniger, M., Bosch, F., Ormanns, S., Mayer, B., Werner, J., Bazhin, A.V., and D\u2019Haese, J.G. (2019). Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer. Cancers, 11.","DOI":"10.3390\/cancers11010039"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Schoenberg, M.B., Hao, J., Bucher, J.N., Miksch, R.C., Anger, H.J.W., Mayer, B., Mayerle, J., Neumann, J., Guba, M.O., and Werner, J. (2018). Perivascular Tumor-Infiltrating Leukocyte Scoring for Prognosis of Resected Hepatocellular Carcinoma Patients. Cancers, 10.","DOI":"10.3390\/cancers10100389"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12254-016-0267-3","article-title":"Immune checkpoint blockade in ovarian cancer","volume":"9","author":"Weiss","year":"2016","journal-title":"Memo"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the Treatment of Non\u2013Small-Cell Lung Cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/9\/1250\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:14:11Z","timestamp":1760188451000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/11\/9\/1250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,26]]},"references-count":53,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["cancers11091250"],"URL":"https:\/\/doi.org\/10.3390\/cancers11091250","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,26]]}}}